We use leading edge genomic testing to help direct personalised treatment using the latest technology
Our Clinical Genomics service is fully UKAS accredited, offering a portfolio of Next Generation Sequencing (NGS) panels and karyotype and Fluorescence In-Situ Hybridisation (FISH) analysis for solid tumours and haematological malignancies. As well as covering all the tests in the NHSE National Genomic Test Directory, we can offer bespoke NGS panels, as directed by treating oncologists. Using the latest technology, we can identify diagnostic markers, treatment targets, and potential resistance mutations, providing a comprehensive overview of the tumour profile. In addition, as part of our Haematological Malignancies Diagnostic Service we offer clonality assessment, mutational status of Ig Variable regions and translocation gene detection at diagnosis and as part of minimal residual disease work up. All reports are interpreted by fully registered, highly experienced Clinical Scientists.
Working closely with experts in oncology at the Royal Marsden and across the North Thames Genomic Laboratory Hub, we can bring novel testing to patients sooner, directing treatment strategies personalised to the patient.
Our rapid circulating tumour DNA (ctDNA) testing service, analyses patient blood samples for genetic changes in fragments of tumour DNA found in the circulation. This liquid biopsy test is currently being used in non-small cell lung cancer at diagnosis, to determine if a patient's tumour has a mutation within the EGFR gene, and at progression, to determine resistance to therapy.
For details of the content of our Next Generation Sequencing panels, including specification, please read the following documents: